{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"556","value":"153"},{"groupId":"OG001","lowerLimit":"50","upperLimit":"1415","value":"283"},{"groupId":"OG002","lowerLimit":"28","upperLimit":"1317","value":"163"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"Time to progression (PFS), defined as the period from the start of the treatment until the criteria for progression are met taking as reference the screening measurements. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment (nadir), and minimum 5 mm increase over the nadir or the appearance of one or more new lesions or appearance of positive bone marrow.","dispersionType":"Full Range","groups":[{"description":"Subjects on study with a diagnosis of Neuroblastoma","id":"OG000","title":"Neuroblastoma"},{"description":"Subjects on study with a diagnosis of a CNS Tumor which included, but was not limited to, Ependymoma, Glioblastoma, Diffuse Midline Glioma, and Other CNS Tumors.","id":"OG001","title":"CNS Tumors"},{"description":"Subjects on study with a diagnosis of a rare solid tumor which included, but was not limited to, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, and Other Rare Tumors.","id":"OG002","title":"Rare Tumors"}],"paramType":"MEAN","populationDescription":"Time on study was measured in days from the date of initial biopsy to date of last administration of study therapy. For subjects with \\>1 biopsies and \\>1 MGT regimens, the off-therapy date from their last treatment was used.","reportingStatus":"POSTED","timeFrame":"From date of start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years","title":"Progression Free Survival (PFS) Interval Will be Measured by Days and Compared to the PFS of Previous Chemotherapy Regimens Since Relapse for Each Patient.","type":"SECONDARY","unitOfMeasure":"Days"}